Hot Scene Biotech (688068.SH): Net profit of RMB 5,0554,800 for the first quarter decreased by 91.42% year-on-year
On April 29, Ge Longhui (688068.SH) released its report for the first quarter of 2024, achieving operating income of 116 million yuan, a year-on-year decrease of 42.78%; net profit attributable to shareholders of listed companies of 50554,800 yuan, a year-on-year decrease of 91.42%; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 339.464 million yuan, with basic earnings per share of 0.06 yuan.
Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Market Cap Dropped CN¥370m Last Week; Retail Investors Bore the Brunt
Key Insights Beijing Hotgen Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 44% of the business is held by the
Hejing Biotech (688068.SH): A total cost of 92.06 million yuan to buy back 3.14% of the shares
Gelonghui, April 16, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on April 15, 2024, the company had repurchased 2,893,010 shares through centralized bidding transactions, accounting for 3.14% of the company's total share capital. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 92,016,460.62 (excluding transaction fees such as stamp duty and transaction commissions).
Splice up the IVD business layout! Hot Scene Biotech “went around the corner” to buy back the former upstream subsidiary
① After acquiring Kaijing Gene, Hejing Biotech rearranged the complete industrial chain from upstream key bioactive ingredients for in vitro diagnosis to R&D, production, and sales of reagents and instruments; ② “In the future, we will also create more business for Kaijing Gene, and revenue and profits are expected to continue to grow.”
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan
Beijing Hotgen Biotech (SHA:688068) plans to acquire Beijing Kaijing Gene Technology from affiliated company Beijing Shunjing Biomedical Technology for 11 million yuan, according to the company's disc
Hejing Biotech (688068.SH) plans to acquire 100% of Kaijing Gene's shares to integrate the in vitro diagnostic business
According to Zhitong Finance App News, Hot View Biotech (688068.SH) announced that in order to integrate the in vitro diagnosis business of the company and related companies, the company plans to acquire 100% of the shares of Beijing Kaijing Gene Technology Co., Ltd. (“Shunjing Gene”) held by the affiliated company Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”). The transfer price for this transaction was 11 million yuan, all of which were paid in cash. According to reports, Kaijing Gene was founded in 2016 and is a biotechnology service company specializing in R&D, production and sales of in vitro diagnostic reagent raw materials. It is proposed for in vitro diagnostic reagent manufacturers
Hot View Biotech (688068.SH): Foreign trade is currently progressing well
Gelonghui, April 11, 丨 Hot View Biotech (688068.SH) Investor Relations Activity Record Sheet shows that the company has always insisted on placing equal emphasis on domestic and foreign markets and is actively expanding overseas markets. Currently, foreign trade is progressing well. The company has established two professional marketing management teams, international and domestic, and has set up subsidiaries in India, Hong Kong and the United States, and set up offices in Thailand to develop global business.
Hot View Biotech (688068.SH): A total cost of 87.02 million yuan to buy back 2.95% of the shares
Gelonghui, April 2, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on March 29, 2024, the company had repurchased 2,718,010 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87,021,704.94 (excluding transaction fees such as stamp duty and transaction fees).
Hot View Biotech (688068.SH): 2.95% of shares have been repurchased
Gelonghui, March 4, 丨 Hot View Biotech (688068.SH) announced that by the close of trading on February 29, 2024, the company had repurchased 2,718,000 shares through centralized bidding transactions, accounting for 2.95% of the company's total share capital, an increase of 0.27% compared with the previous disclosure. The highest price of the repurchase transaction was 33.79 yuan/share, the lowest price was 27.28 yuan/share, and the total amount of capital paid was RMB 87.0217 million (excluding transaction fees such as stamp duty and transaction fees).
Hot View Biotech (688068.SH) performance report: 2023 net profit of 30.1612 million yuan fell 96.81% year on year
Gelonghui, Feb. 28, 丨 Greenview Biotech (688068.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 541.1467 million yuan, a decrease of 84.78% compared with the same period last year; realized net profit attributable to owners of the parent company of 30.1612 million yuan, a decrease of 96.81% compared with the same period last year; realized net profit attributable to the owners of the parent company after deducting non-recurring gains and losses - 56.4366 million yuan, a decrease of 105.99% compared with the same period last year.
Hejing Biotech (688068.SH) has repurchased 2.68% of its shares at a cost of 79.11 million yuan
Hotview Biotech (688068.SH) announced that as of the close of trading on February 19, 2024, the company passed centralized bidding...
Hot View Biotech (688068.SH): Initial repurchase of 971,600 shares
Gelonghui, Feb. 19, 丨 Hot View Biotech (688068.SH) announced that on February 8, 2024, the company repurchased 971,600 shares for the first time through centralized bidding transactions, accounting for 1.05% of the company's total share capital. The highest purchase price was RMB 31.64 yuan/share, the lowest price was RMB 27.28 per share, and the total amount paid was RMB 29.708 million (excluding transaction fees such as stamp duty and transaction commissions).
The medical device sector strengthened, and many other stocks such as Melander rose and stopped
Gelonghui, Feb. 8 | Mailand Biotech rose and stopped 20CM, Zhende Medical and Matilda Biotech went up and down, and Yingkang Life, Lanwei Medicine, and Maipu Medical surged more than 10%. According to news, in January 2024, the State Drug Administration approved the registration of a total of 321 medical device products. Among them, there are 247 domestic Class III medical device products, 41 imported Class III medical device products, and 33 Class II medical device products.
Nearly 40 listed companies revealed plans to repurchase or increase their holdings of Artes after the market for 500 to 1 billion yuan
Gelonghui, Feb. 7 | According to incomplete statistics, post-market statistics include Artes, Hangjin Technology, Happy Home, Yuyuan Garden Co., Ltd., Junyao Health, Ed Biotech, Dafeng Industrial, Donggang, Lansheng, Huanxu Electronics, Changgao Dianxin, Novo Zhiyuan, Panmicro Network, Hejing Biotech, Yongguan New Materials, Oriental Biotech, Jingwei Hengrun, Hongrun Construction, Simei Media, Chinese Media, Huayuan Holdings, Bose Co., Ltd., Suzhou Keda, Pu Nai Co., Ltd., Fuda Co., Ltd., Jiaxin Silk, Jinshan Office, Shanggong Shenbei, Shentong Technology, Xintian Pharmaceutical, Liancheng Precision, Huamao Co., Ltd., Taifu Pump Industry, Yuanjie Technology, Yidong Electric
Express News | Hejing Biotech: It plans to repurchase shares for 75 million yuan to 150 million yuan. The repurchase price of shares will not exceed RMB 53 per share.
Hot View Biotech (688068.SH): Plans to transfer 10% of Yaojing Gene's shares for 10 million yuan
Gelonghui, Feb. 5, 丨 Hot View Biotech (688068.SH) announced that the company and Mr. Lin Changqing signed an “Equity Transfer Agreement” in Beijing on February 2, 2024. The company plans to transfer 10% of its Yaojing Gene shares to Mr. Lin Changqing at a consideration of RMB 10 million. Mr. Lin Changqing is the actual controller, chairman and general manager of the company, and is a natural person related to the company; this transaction constitutes a related transaction and does not constitute a major asset restructuring.
Hejing Biotech (688068.SH) and its subsidiaries have recently obtained 13 medical device registration certificates and 60 overseas qualification certifications
Hejing Biotech (688068.SH) issued an announcement. The company and its subsidiaries will be held from November 2023 to 2024...
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) Might Not Be As Mispriced As It Looks After Plunging 29%
Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) shareholders that were waiting for something to happen have been dealt a blow with a 29% share price drop in the last month. The recent drop completes
Hejing Biotech (688068.SH) issued a pre-cut. Net profit is expected to be 24 million yuan to 36 million yuan in 2023, a sharp drop of 96.19% to 97.46% year on year
Hot View Biotech (688068.SH) released its 2023 annual performance forecast and is expected to achieve ownership in 2023...
Hot Scene Biology (688068.SH): Currently, there is no brain-computer interface layout
On November 30, Gelonghui (688068.SH) said on an interactive platform that the company, as the first IVD company listed on the Science and Technology Innovation Board, has always used scientific and technological innovation as the company's development concept, strengthened the main in vitro diagnostic business, and expanded new fields and strategic layout based on biotechnology trends. Currently, there is no brain-computer interface.
No Data